Peptides for Hormone Optimization: The Complete Protocol for Men and Women

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Comprehensive hormone optimization combines sex hormone replacement (TRT/HRT), growth hormone optimization (GH secretagogues), thyroid optimization, adrenal support (DHEA), and peptide therapy (BPC-157, Thymosin Alpha-1). This multi-system approach addresses the full spectrum of age-related hormonal decline.

The Hormonal Decline of Aging

Aging is characterized by the progressive decline of multiple hormonal systems simultaneously: testosterone (1–2% per year in men after age 30), estrogen and progesterone (dramatic decline at menopause in women), growth hormone (1–2% per year after age 30), DHEA (approximately 2% per year after age 25), thyroid hormones (subclinical hypothyroidism becomes increasingly common with age), and melatonin (significant decline after age 40). Addressing only one of these systems while ignoring the others produces suboptimal results — comprehensive hormone optimization requires a systems-level approach.

Sex Hormone Foundation

For men: testosterone replacement therapy (when indicated) is the foundation of male hormone optimization. Target: total testosterone 600–900 ng/dL, free testosterone in the upper quartile, estradiol 20–40 pg/mL. For women: body-identical HRT (transdermal estradiol + micronized progesterone, with testosterone if libido or energy is impaired) is the foundation of female hormone optimization during and after menopause.

Growth Hormone Optimization

GH secretagogues (CJC-1295 + Ipamorelin, 100 mcg each before bed) provide a physiological approach to GH optimization that is appropriate for both men and women. Benefits include improved body composition, enhanced recovery, better sleep quality, and anti-aging effects on skin and connective tissue. This approach is preferred over synthetic HGH for most individuals because it works with the body's natural feedback mechanisms.

Thyroid and Adrenal Optimization

Thyroid optimization (ensuring TSH is 1–2 mIU/L, free T3 in the upper third of the reference range) and adrenal support (DHEA 25–50 mg daily, stress management) complete the hormonal foundation. Subclinical hypothyroidism and DHEA deficiency are commonly overlooked contributors to the symptoms of aging.

Peptide Adjuncts

Peptide therapy complements hormonal optimization: BPC-157 (500 mcg daily) for systemic anti-inflammatory and healing support, Thymosin Alpha-1 (1.6 mg twice weekly) for immune rejuvenation, Epitalon (5–10 mg daily for 10–20 day cycles, twice yearly) for telomere and circadian regulation, and GHK-Cu (topically and/or systemically) for skin and tissue health. Together, these interventions address the full spectrum of age-related decline.